Efficacy of novel P-glycoprotein inhibitors to increase the oral uptake of paclitaxel in mice
Heleen A. Bardelmeijer(Slotervaartziekenhuis), Olaf van Tellingen(Dutch Cancer Society), Jan H.M. Schellens(Utrecht University), Mariët Ouwehand, Jos H. Beijnen(The Netherlands Cancer Institute)
Cited by 80
Related Papers
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
|New England Journal of Medicine|2019|1.5k
Overcoming the blood–brain tumor barrier for effective glioblastoma treatment
|Drug Resistance Updates|2015|1k
Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins
|Proceedings of the National Academy of Sciences|1997|941
Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine
|Proceedings of the National Academy of Sciences|1997|884